Identification

Name
Streptozocin
Accession Number
DB00428  (APRD00209)
Type
Small Molecule
Groups
Approved
Description

An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. [PubChem]

Structure
Thumb
Synonyms
  • 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
  • 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
  • Estreptozocina
  • N-D-Glucosyl-(2)-n'-nitrosomethylurea
  • N-D-Glucosyl-(2)-n'-nitrosomethylharnstoff
  • Streptozocin
  • Streptozocine
  • Streptozocinium
  • Streptozocinum
  • Streptozotocin
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZanosarPowder, for solution100 mg/mLIntravenousTeva Parenteral Medicines, Inc.2003-12-03Not applicableUs
Zanosar Sterile PowderPowder, for solution1 gIntravenousPaladin Labs Inc1985-12-31Not applicableCanada
International/Other Brands
Zanosar
Categories
UNII
8H27GUR065
CAS number
18883-66-4
Weight
Average: 265.2206
Monoisotopic: 265.090999849
Chemical Formula
C8H15N3O7
InChI Key
ZSJLQEPLLKMAKR-GKHCUFPYSA-N
InChI
InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
IUPAC Name
3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
SMILES

Pharmacology

Indication

For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).

Structured Indications
Pharmacodynamics

Streptozocin is an antitumour antibiotic consisting of a nitrosourea moiety interposed between a methyl group and a glucosamine. Streptozocin is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Streptozocin inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine moieties leads to degradation of DNA. The biochemical mechanism leading to mammalian cell death has not been definitely established; streptozocin inhibits cell proliferation at a considerably lower level than that needed to inhibit precursor incorporation into DNA or to inhibit several of the enzymes involved in DNA synthesis. Although streptozocin inhibits the progression of cells into mitosis, no specific phase of the cell cycle is particularly sensitive to its lethal effects.

Mechanism of action

Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
USolute carrier family 2, facilitated glucose transporter member 2
ligand
Human
AO-GlcNAcase BT_4395
antagonist
Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / NCTC 10582 / E50 / VPI-5482)
UBifunctional protein NCOATNot AvailableHuman
Absorption

Poor oral absorption (17-25%)

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic

Route of elimination

As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.

Half life

5-15 minutes

Clearance
Not Available
Toxicity

Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Streptozocin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Streptozocin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Streptozocin.Approved
AlclofenacAlclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumStreptozocin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidStreptozocin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Streptozocin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Streptozocin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Streptozocin.Approved, Investigational
AmpicillinThe serum concentration of Streptozocin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Streptozocin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumStreptozocin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateStreptozocin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Streptozocin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Streptozocin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Streptozocin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Streptozocin.Investigational
BendazacBendazac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Streptozocin.Approved, Investigational
BevoniumBevonium may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Botulinum Toxin Type AStreptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BStreptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Streptozocin.Approved
BromfenacBromfenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptozocin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Streptozocin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Streptozocin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Streptozocin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinStreptozocin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Streptozocin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
CisatracuriumStreptozocin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateStreptozocin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Streptozocin.Approved
Clodronic AcidStreptozocin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Streptozocin.Approved
CloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Streptozocin is combined with Clozapine.Approved
ColistimethateStreptozocin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Streptozocin.Approved
CurcuminCurcumin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Streptozocin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Streptozocin.Approved, Investigational
CyclosporineStreptozocin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Streptozocin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.Approved
DecamethoniumStreptozocin may increase the respiratory depressant activities of Decamethonium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Streptozocin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Streptozocin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Streptozocin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Streptozocin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Streptozocin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.Approved, Investigational
Domoic AcidStreptozocin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideStreptozocin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Streptozocin.Approved, Investigational
DroxicamDroxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Streptozocin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptozocin.Approved
EtanerceptEtanercept may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Etidronic acidStreptozocin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
FingolimodStreptozocin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Streptozocin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptozocin.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Streptozocin.Investigational
GallamineStreptozocin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideStreptozocin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Streptozocin.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Streptozocin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Streptozocin.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Streptozocin.Approved, Withdrawn
HigenamineHigenamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
IbandronateStreptozocin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Streptozocin.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Streptozocin.Investigational
IsoxicamIsoxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Streptozocin.Experimental
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Streptozocin.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Streptozocin is combined with Leflunomide.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Streptozocin.Approved
LisofyllineLisofylline may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Streptozocin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
MecamylamineStreptozocin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Streptozocin.Investigational, Withdrawn
MetampicillinThe serum concentration of Streptozocin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Streptozocin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Streptozocin.Experimental
MetocurineStreptozocin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideStreptozocin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Streptozocin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumStreptozocin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Streptozocin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.Approved, Investigational
NeosaxitoxinStreptozocin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Streptozocin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Streptozocin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Streptozocin.Approved
OxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin.Approved, Vet Approved
PamidronateStreptozocin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumStreptozocin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Streptozocin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Streptozocin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Streptozocin.Experimental
PhenoxymethylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.Approved, Investigational
PipecuroniumStreptozocin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Streptozocin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptozocin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Streptozocin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Streptozocin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Streptozocin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Streptozocin.Experimental
PTC299PTC299 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
PyrantelStreptozocin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Streptozocin is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Streptozocin.Approved
RapacuroniumStreptozocin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Experimental, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Streptozocin.Investigational
RisedronateStreptozocin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumStreptozocin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Streptozocin.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Streptozocin.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Streptozocin.Approved
SalicylamideSalicylamide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Streptozocin.Approved
SalsalateSalsalate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Streptozocin.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Streptozocin.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Streptozocin.Investigational
SRT501SRT501 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
SuccinylcholineStreptozocin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Streptozocin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Streptozocin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Streptozocin.Approved, Investigational
TalampicillinThe serum concentration of Streptozocin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Streptozocin can be decreased when it is combined with Tazobactam.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Streptozocin.Investigational
Technetium Tc-99m etidronateStreptozocin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateStreptozocin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Streptozocin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Streptozocin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Streptozocin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidStreptozocin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
TofacitinibStreptozocin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptozocin.Approved
TranilastTranilast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Streptozocin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Streptozocin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational
TubocurarineStreptozocin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Streptozocin.Approved
VecuroniumStreptozocin may increase the respiratory depressant activities of Vecuronium.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Streptozocin.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Streptozocin.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidStreptozocin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Withdrawn
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Streptozocin.Approved
Food Interactions
Not Available

References

General References
  1. Brentjens R, Saltz L: Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001 Jun;81(3):527-42. [PubMed:11459269]
  2. Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6. [PubMed:9421374]
  3. Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33. [PubMed:7926307]
  4. VAVRA JJ, DEBOER C, DIETZ A, HANKA LJ, SOKOLSKI WT: Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959-1960;7:230-5. [PubMed:13841501]
  5. Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968 Mar 30;1(7544):670-1. [PubMed:4170654]
  6. Link [Link]
External Links
Human Metabolome Database
HMDB14572
KEGG Drug
D05932
KEGG Compound
C07313
PubChem Compound
29327
PubChem Substance
46508872
ChemSpider
27273
ChEBI
9288
ChEMBL
CHEMBL1603
Therapeutic Targets Database
DAP000984
PharmGKB
PA451514
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Streptozocin
ATC Codes
L01AD04 — Streptozocin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
MSDS
Download (76.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentColorectal Cancers1
2CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Glioblastoma Multiforme / Mixed Gliomas / Recurrent Brain Tumors1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor1
2CompletedTreatmentNeoplasms1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
3CompletedTreatmentCarcinoma, Adrenal Cortical1

Pharmacoeconomics

Manufacturers
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous100 mg/mL
Powder, for solutionIntravenous1 g
Prices
Unit descriptionCostUnit
Zanosar 1 gm powder vial78.82USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)115 °CPhysProp
water solubility5070 mg/LNot Available
logP-1.45HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility33.5 mg/mLALOGPS
logP-1.7ALOGPS
logP-2.7ChemAxon
logS-0.9ALOGPS
pKa (Strongest Acidic)11.43ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.96 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8406
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6495
P-glycoprotein substrateNon-substrate0.6244
P-glycoprotein inhibitor INon-inhibitor0.7667
P-glycoprotein inhibitor IINon-inhibitor0.9787
Renal organic cation transporterNon-inhibitor0.9509
CYP450 2C9 substrateNon-substrate0.6998
CYP450 2D6 substrateNon-substrate0.846
CYP450 3A4 substrateNon-substrate0.5462
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9636
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9893
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9182
BiodegradationReady biodegradable0.7191
Rat acute toxicity2.6715 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.793
hERG inhibition (predictor II)Non-inhibitor0.9288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Hexoses
Alternative Parents
N-methylnitrosoureas / Oxanes / Semicarbazides / Nitrosamides / Secondary alcohols / Hemiacetals / Polyols / Oxacyclic compounds / Primary alcohols / Organopnictogen compounds
show 3 more
Substituents
Hexose monosaccharide / N-methylnitrosourea / Nitrosourea / Oxane / Nitrosamide / Semicarbazide / Organic n-nitroso compound / Hemiacetal / Carbonic acid derivative / Secondary alcohol
show 13 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
N-nitrosoureas, N-acylglucosamine (CHEBI:9288)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Bennett RA, Pegg AE: Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981 Jul;41(7):2786-90. [PubMed:6454479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
Hexose transmembrane transporter activity
Specific Function
Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta c...
Gene Name
SLC2A2
Uniprot ID
P11168
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 2
Molecular Weight
57488.955 Da
References
  1. Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6. [PubMed:9421374]
  2. Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33. [PubMed:7926307]
Kind
Protein
Organism
Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / NCTC 10582 / E50 / VPI-5482)
Pharmacological action
Yes
Actions
Antagonist
General Function
Beta-n-acetylglucosaminidase activity
Specific Function
Can hydrolyze the glycosidic link of O-GlcNAcylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates (in vitro).
Gene Name
Not Available
Uniprot ID
Q89ZI2
Uniprot Name
O-GlcNAcase BT_4395
Molecular Weight
84484.62 Da
References
  1. He Y, Martinez-Fleites C, Bubb A, Gloster TM, Davies GJ: Structural insight into the mechanism of streptozotocin inhibition of O-GlcNAcase. Carbohydr Res. 2009 Mar 31;344(5):627-31. doi: 10.1016/j.carres.2008.12.007. Epub 2008 Dec 13. [PubMed:19217614]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Hyalurononglucosaminidase activity
Specific Function
Isoform 1: Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrop...
Gene Name
MGEA5
Uniprot ID
O60502
Uniprot Name
Protein O-GlcNAcase
Molecular Weight
102914.215 Da
References
  1. Pathak S, Dorfmueller HC, Borodkin VS, van Aalten DM: Chemical dissection of the link between streptozotocin, O-GlcNAc, and pancreatic cell death. Chem Biol. 2008 Aug 25;15(8):799-807. doi: 10.1016/j.chembiol.2008.06.010. [PubMed:18721751]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Choi YH, Lee AK, Bae SK, Kim SO, Lee MG: Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos. 2005 Apr;26(3):93-8. [PubMed:15674819]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Choi YH, Lee AK, Bae SK, Kim SO, Lee MG: Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos. 2005 Apr;26(3):93-8. [PubMed:15674819]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Kataoka S, Yasui H, Hiromura M, Sakurai H: Effect of insulin-mimetic vanadyl sulfate on cytochrome P450 2E1-dependent p-nitrophenol hydroxylation in the liver microsomes of streptozotocin-induced type 1 diabetic rats. Life Sci. 2005 Oct 14;77(22):2814-29. [PubMed:15964029]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos. 2002 Jul;30(7):838-44. [PubMed:12065443]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33